A.O. Ordine Mauriziano di Torino

Titolo:	Phase 3 Randomized, Double-Blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
Codice studio	KO-MEN-17
Patologia:	Leucemia mieloide acuta
Tipo di Studio:	Interventistico
Tipologia	Profit
Fase:	3
Principali criteri di inclusione:	• Diagnosis of AML per the 2022 WHO Classification. • Creatinine clearance ≥ 30 mL/min • If the patient is a candidate for non-intensive therapy (VEN+AZA): Documented NPM1-m • If the patient is a candidate for intensive therapy (7+3): Documented NPM1-m or KMT2A-r (patient with a partial tandem duplication [PTD] are not eligible); Documented FLT3 wild-type or ITD ratio <0.05 OR ineligible to receive FLT3-targeted therapy
Principali criteri di esclusione:	• Diagnosis of either acute promyelocytic leukemia (APL), blast phase chronic myeloid leukemia, or isolated myeloid sarcoma • Known history of BCR-ABL mutation • Patient who has been previously treated (including chemotherapy, targeted drugs, monoclonal antibodies and investigational drugs, excluding supportive treatments and hydroxycarbamide) for hematologic disorders, such as AML or MDS
Struttura	SCDU Ematologia e Terapie Cellulari
Contatto	Prof.ssa Daniela Cilloni daniela.cilloni@unito.it